Speakers

Floor J. Backes, Beth Karlan, Ursula Matulonis, Bradley J. Monk, Bobbie Rimel, Angeles Alvarez Secord, Melinda Telli, Andrea Wahner Hendrickson, Robert Wenham, Shannon N. Westin

Floor J. Backes, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Dr. Backes is a gynecologic oncologist and clinical investigator at The Ohio State University and James Comprehensive Cancer Center in Columbus, Ohio. She is fully committed to provide the best care for her patients through a combination of excellent clinical care, developing and collaborating on clinical trials and translational research projects, to provide her patients with improved and novel treatment opportunities. Dr. Backes has a strong interest in the development of novel therapies for gynecologic cancers and clinical trials. She has experience in developing and leading clinical trials, and has been successful in collaborations in translational science projects. Dr. Backes was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017 and was listed on Best Doctors in America List in 2017.

Back to top

Beth Karlan, MD

Board of Governors’ Endowed Chair in Gynecologic Oncology
Director
Women’s Cancer Program at the Samuel Oschin Cancer Institute, Division of Gynecologic Oncology, and Gilda Radner Hereditary Cancer Program
Professor, Obstetrics and Gynecology
Cedars-Sinai Medical Center and David Geffen School of Medicine at the University of California–Los Angeles
Los Angeles, California

Dr. Karlan is Director of the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, the Division of Gynecologic Oncology, and the Gilda Radner Hereditary Cancer Program, and holds the Board of Governors’ Endowed Chair in Gynecologic Oncology at Cedars-Sinai Medical Center in Los Angeles, California. She also is a professor of obstetrics and gynecology at the David Geffen School of Medicine at the University of California–Los Angeles. Dr. Karlan's research focuses on ovarian and other women's cancers, as well as inherited cancer susceptibility. She has authored more than 300 research publications and is an American Cancer Society Clinical Research Professor. She is the editor-in-chief of the scientific journals Gynecologic Oncology and Gynecologic Oncology Reports. In 2012, Dr. Karlan was appointed by the White House to serve on the National Cancer Advisory Board, and in 2015, she was elected to membership in the National Academy of Medicine.

Back to top

Ursula Matulonis, MD

Medical Director and Program Leader Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Matulonis is Medical Director and Disease Center Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts. She also is the interim director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale drug development and selection.

Dr. Matulonis is Principal Investigator (PI) of several therapeutic clinical trials and translational studies for ovarian cancer. She is the overall PI on a Program Project Development Grant funded by the Ovarian Cancer Research Foundation entitled “Rational Combinations of Novel Biologic Agents for Ovarian Cancer Therapy.” She is the PI on the project “Genetic Similarities between Serous Ovarian Cancer and Triple-Negative Breast Cancer” funded by the Breast Cancer Research Foundation. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline committee for ovarian cancer, the Massachusetts ovarian cancer Task Force, the Gynecologic Oncology Group ovarian committee, the National Cancer Institute Ovarian Cancer Task Force, the Scientific Advisory Board of the Ovarian Cancer Research Foundation, the Scientific Board of the Clearity Foundation, and is Medical Director and a board member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Leonard P. Zakim Patient Advocacy Award, and the Susan M. Love Award from Fenway Health.

After receiving her medical degree from Albany Medical College in Albany, New York, she completed an internship and residency at the University of Pittsburgh in Pittsburgh, Pennsylvania, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute.

Back to top

Bradley J. Monk, MD, FACS, FACOG

Professor
Arizona Oncology (US Oncology Network)
US Oncology Medical Director of Gynecologic Oncology Research
University of Arizona College of Medicine–Phoenix
Creighton University School of Medicine at St. Joseph’s Hospital
Phoenix, Arizona

Dr. Monk graduated at the top of his class from the University of Arizona College of Medicine in Tucson, Arizona, in 1988, and completed a residency in obstetrics and gynecology at the University of California in Los Angeles, California, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in medical genetics and gynecologic oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center in Lubbock, Texas; and from 1998 to 2010, he was Associate Professor with Tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology in Irvine, California. Dr. Monk then was appointed Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. In 2016, he became a member of Arizona Oncology and part of the US Oncology Network and continues to practice in Phoenix. Most recently, he has been appointed the US Oncology Medical Director of Gynecologic Oncology Research. Dr. Monk also is a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine in Phoenix and works at Arizona Oncology. He has been named one of Arizona’s “Top Doctors” by PHOENIX magazine 5 years in a row beginning in 2012.

Back to top

Bobbie Rimel, MD

Board of Governors’ Endowed Chair in Gynecologic Oncology
Director
Women’s Cancer Program at the Samuel Oschin Cancer Institute, Division of Gynecologic Oncology, and Gilda Radner Hereditary Cancer Program
Professor, Obstetrics and Gynecology
Cedars-Sinai Medical Center and David Geffen School of Medicine at the University of California–Los Angeles
Los Angeles, California

Dr. Rimel graduated from Duke University Medical School Durham, North Carolina in 2003. She completed her residency in Obstetrics and Gynecology at Northwestern University in Evanston, Illinois in 2007 and her fellowship in Gynecologic Oncology at Washington University in St. Louis, Missouri in 2011. She is currently an Assistant Professor and practicing gynecologic oncologist at Cedars-Sinai Medical Center in Los Angeles, California. Her research focuses in ovarian and endometrial cancers and clinical trial accrual.

Back to top

Angeles Alvarez Secord, MD, MHSc

Professor
Division of Gynecologic Oncology
Director of Gynecologic Oncology Clinical Trials
Associate Director of Clinical Research, Gynecology Oncology
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Dr. Secord is a professor in the Division of Gynecologic Oncology at Duke University Medical Center in Durham, North Carolina. She received her undergraduate degree in Biology with Honors from Carroll College in Waukesha, Wisconsin, and graduated AOA with Honors from the University of Washington School of Medicine in Seattle, Washington. She completed her residency in obstetrics and gynecology and a fellowship in gynecologic oncology at Duke University Medical Center in Durham, North Carolina. Upon completing the oncology fellowship in 2001, she accepted a faculty position within the Division of Gynecologic Oncology at Duke.

Dr. Secord has received awards from Duke University Medical Center, the Mid-Atlantic Gynecologic Oncology Society, the Society of Gynecologic Oncology, the Gynecologic Oncology Group, and the Foundation for Women’s Cancer for her research in angiogenesis in ovarian carcinoma. She currently is the Director of Gynecologic Oncology Clinical Trials, the Associate Director of Clinical Research, Gynecology Oncology, and a principal investigator for NRG Oncology at the Duke Cancer Institute. Additionally, she serves on NRG Oncology’s Developmental Therapeutics Committee and Ovarian Cancer Committee. She was appointed Co-Chair of NRG Oncology’s New Investigator Committee and is dedicated to mentoring future oncology leaders. Dr. Secord also has served on the National Cancer Institute’s Ovarian Cancer Task Force.

Dr. Secord’s research interests include development of novel therapeutics and biomarkers in ovarian cancer, novel clinical trial designs, the role of obesity in gynecologic malignancies, and the development of patient-centric composite clinical endpoints. Dr. Secord is a fellow of the American College of Obstetricians and Gynecologists and is an active member of the Society of Gynecologic Oncology, the American Society of Clinical Oncology, the International Gynecologic Cancer Society, and other professional organizations. Dr. Secord has authored more than 150 peer-reviewed articles and has been the recipient of numerous clinical trial and basic research grants.

Back to top

Melinda Telli, MD

Assistant Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, California

Dr. Telli is an assistant professor of medicine in the Division of Medical Oncology at Stanford University School of Medicine in Stanford, California. Her research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Dr. Telli’s work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from platinum chemotherapy. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she also has explored the use of “beyond BRCA” DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.

Dr. Telli received her undergraduate degree from the University of Pennsylvania in Philadelphia, Pennsylvania, as magna cum laude, and her medical degree from George Washington University in Washington, DC, with distinction. She completed an internship and residency in internal medicine at Stanford University, and continued at Stanford to pursue fellowship training in medical oncology. She has served on numerous American Society of Clinical Oncology committees and currently serves as a Komen Scholar and as a member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Grant (2008), American Society of Clinical Oncology Young Investigator Award (2009), and Susan G. Komen for the Cure Leadership Award (2015). She has garnered multiple teaching accolades is a repeat recipient of the Stanford Division of Oncology Teaching Award.

Back to top

Andrea Wahner Hendrickson, MD

Assistant Professor of Medical Oncology and Pharmacology
Mayo Clinic
Rochester, Minnesota

Back to top

Robert Wenham, MD, MS, FACS, FACOG

Chair and Director of Research, Department of Gynecologic Oncology
Senior Member, Chemical Biology and Molecular Medicine Program
Moffitt Cancer Center
Tampa, Florida

Dr. Wenham is a department chair and director of research in gynecologic oncology at the Moffitt Cancer Center in Tampa, Florida. After undergraduate and graduate training in biochemistry and molecular biology, he completed his medical doctorate at Southwestern Medical School in Dallas, Texas. He then completed an internship and residency at the Harvard Medical School integrated residency program (The Brigham and Women's Hospital/Massachusetts General Hospital) in obstetrics and gynecology in Boston, Massachusetts, and his fellowship in gynecologic oncology at Duke University in Durham, North Carolina. He currently is in the Department of Gynecologic Oncology at the Moffitt Cancer Center. His academic career consists of clinical gynecologic oncology; the training of fellows, residents, and medical students; research-related administrative and service roles; and clinical/translational research in oncology. He is a principal investigator (PI) on several consortia, industry, and investigator­initiated trials. He has been the lead Pl for one of the largest prospective cancer tissue and data trials (TCCP) ever conducted, and that trial is setting the foundation for discovery in the epidemiology, detection, and treatment of malignancies. He also serves on national and international advisory boards and steering committees, as well as being an active member of several professional societies.

Back to top

Shannon N. Westin, MD, MPH, FACOG

Associate Professor
Director of Early Drug Development and Phase I Trials
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Westin earned her medical degree from the University of Florida College of Medicine in Gainesville, Florida. She completed her obstetrics and gynecology residency at the University of North Carolina at Chapel Hill, North Carolina, and a fellowship in gynecologic oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. During fellowship, she received a master of public health degree with a concentration in epidemiology, from the University of Texas School of Public Health. In addition to her training in gynecologic oncology, she also completed a short fellowship in investigational cancer therapeutics. She joined the faculty at the University of Texas MD Anderson Cancer Center in 2010. She has been honored as an NIH K12 Calabresi Scholar and an Andrew Sabin Family Fellow.
Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the director of Early Drug Development and Phase I Trials in her department and serves on the NRG Oncology/Gynecologic Oncology Group committees for Developmental Therapeutics and for Phase I. She is the co-principal investigator (PI) for major projects in her institution’s SPOREs (Specialized Programs of Research Excellence) in uterine cancer and in ovarian cancer. Dr. Westin also serves as the PI or co-PI for more than 20 novel treatment trials in gynecologic malignancies.
Dr. Westin has authored or co-authored more than 70 scientific publications, book chapters, and invited articles. She has been invited to lecture as an expert on targeted therapy in gynecologic malignancies and survivorship in local, national, and international venues. She is an active member of the Society of Gynecologic Oncology (SGO) and has served on SGO’s communications committee. In 2016, she completed the American Society of Clinical Oncology (ASCO) Leadership Development Program and serves on four ASCO committees, including Cancer Communications, Guideline Advisory Group for gynecologic cancers, Social Media Working Group, and Workforce Advisory Group.

Back to top